Sugi Predict

Sugi Predict / Compounds / SCHEMBL286068

SCHEMBL286068

SCHEMBL286068

CCOC(=O)c1cnc(C)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 3/20 0.60
▸ DBF4 Q9UBU7 3/20 0.60
▸ HCAR2 Q8TDS4 1/20 0.58
▸ HDAC3 O15379 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ GABRP O00591 1/20 0.41
▸ GABRD O14764 1/20 0.41
▸ GABRA1 P14867 1/20 0.41
▸ GABRB1 P18505 1/20 0.41
▸ GABRG2 P18507 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20267928 0.88 HCAR2 (0.53) CDC7DBF4HCAR2HDAC3HDAC4
SCHEMBL16933028 0.85 CDC7 (0.60) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL274346 0.84 CDC7 (0.59) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL6476591 0.84 CDC7 (0.59) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL222203 0.82 SMN1; SMN2 (0.58) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL13451804 0.82 HCAR2 (0.55) CDC7DBF4HCAR2HDAC3HDAC4
SCHEMBL1912617 0.82 CDC7 (0.57) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL21963019 0.82 CDC7 (0.57) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL3332696 0.82 CDC7 (0.57) CDC7DBF4HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL1519816 0.82 CDC7 (0.57) CDC7DBF4HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
CN-110869363-B 5-membered and bicyclic heterocyclic amides as ROCK inhibitors 百时美施贵宝公司 2024-01-05 — — CN disclosed
EP-4298097-A1 BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2024-01-03 — — EP disclosed
US-20230391764-A1 BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-12-07 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
CN-116897155-A Benzothiazolyl bicyclo [1.1.1] pentane derivatives for the treatment and prevention of hepatitis b virus infection 豪夫迈·罗氏有限公司 2023-10-17 — — CN disclosed
WO-1994014436-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1994-07-07 — — WO disclosed
US-4600025-A 2-METHYL-5(HETEROMETHYL)THIAZOLE GRIGG RONALD E 1986-07-15 — — US disclosed
EP-0034481-B1 2-METHYL-5-THIAZOLE-METHYLAMINE AND CARBOXAMIDE DERIVATIVES Grigg, Ronald Ernest (GB) 1984-05-30 — — EP disclosed
EP-0034481-A1 2-Methyl-5-thiazole-methylamine and carboxamide derivatives Grigg, Ronald Ernest (GB) 1981-08-26 — — EP disclosed
US-4073919-A Hypolipemiant compositions and methods ROUSSEL UCLAF (FR) 1978-02-14 — — US disclosed
US-4053618-A ANTILIPOLYTIC ROUSSEL-UCLAF (FR) 1977-10-11 — — US disclosed
US-4051249-A SALTS OF 2-ALKYLTHIAZOLE-5-METHANOL DERIVATIVES ROUSSEL-UCLAF (FR) 1977-09-27 — — US disclosed
US-4046902-A VASODILATORS ROUSSEL UCLAF (FR) 1977-09-06 — — US disclosed
US-4032643-A ANTILIPOLYTIC AGENTS, VASODILATION, ANTIBRADYKINETIC AGENTS ROUSSEL-UCLAF (FR) 1977-06-28 — — US disclosed
US-3957809-A VASODILATORS ROUSSEL-UCLAF (FR) 1976-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS CDC7 1688/4885DBF4 945/4885HCAR2 2735/4885
US-20230391764-A1 BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HAVCR2, SLC10A1, BCL2A1 CDC7 4397/4885DBF4 2909/4885HCAR2 858/4885
US-11814376-B2 Hepatitis b core protein modulators HAVCR2, FABP1, MAVS CDC7 1688/4885DBF4 945/4885HCAR2 2735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.